Eye Health Supplements: A Pharmacist’s Guide to Lutein, Zeaxanthin, Astaxanthin, and Omega-7

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Why Eye Health Deserves More Attention Than It Gets

Age-related eye disease, dry eye, and digital eye strain are common and clinically important conditions affecting millions of Americans. AMD is the leading cause of irreversible vision loss in adults over 50, affecting over 11 million Americans. Dry eye disease affects an estimated 16 million Americans. Screen use — averaging over 7 hours per day for many adults — is strongly associated with eye strain and dry eye symptoms.

Nutrition plays a meaningful role in retinal health, and specific supplements have evidence for selected populations and outcomes. However, supplementation does not eliminate risk and should not replace ophthalmic evaluation or established treatment. This article reviews the human clinical evidence for each key ingredient and clarifies who benefits most.

The Eye's Natural Defense System

The macula — the central region of the retina responsible for sharp, detailed vision — contains a high concentration of specialized pigments called macular pigments, primarily lutein and zeaxanthin. These pigments serve two functions:

• Short-wavelength light absorption: Macular pigments absorb portions of short-wavelength visible light and have antioxidant properties that may help reduce photo-oxidative stress in retinal tissue.
• Antioxidant protection: The retina is one of the most metabolically active tissues in the body. Macular pigments help neutralize reactive oxygen species, providing a layer of protection against oxidative damage.

The body cannot synthesize lutein or zeaxanthin — they must be obtained from diet or supplementation. Modern diets may provide relatively low intakes of lutein and zeaxanthin, particularly in those with limited consumption of dark leafy greens and colorful vegetables.

Key Eye Health Nutrients: The Clinical Evidence

Lutein & Zeaxanthin

Lutein and zeaxanthin are the primary carotenoids in the macula and lens, found in kale, spinach, corn, orange peppers, and egg yolks. They are the most extensively studied eye health nutrients.

AREDS2 — What the Trial Actually Found

The Age-Related Eye Disease Study 2 (AREDS2, PMID 23644932) was a randomized controlled trial of 4,203 participants aged 50–85 at high risk for progression to advanced AMD, with a median follow-up of 5 years. In the primary factorial comparison, adding lutein (10 mg) + zeaxanthin (2 mg) to the AREDS supplement formulation did not significantly reduce progression to advanced AMD versus placebo (HR 0.90; 98.7% CI 0.76–1.07; P=.12).

The clinically meaningful benefit emerged in secondary and exploratory analyses (PMID 24310343): direct comparison of lutein/zeaxanthin versus beta-carotene showed HR 0.82 for AMD progression, and in the subgroup with bilateral large drusen, HR 0.76 for late AMD — approximately a 24% relative reduction. These were secondary, not primary, endpoints.

Importantly, the 10-year AREDS2 follow-up (PMID 35653117) found that beta-carotene nearly doubled lung cancer odds in former smokers, while lutein/zeaxanthin did not show that signal. This strongly supports using lutein/zeaxanthin as the safer replacement for beta-carotene in AREDS-type supplementation.

Macular Pigment Optical Density (MPOD)

The evidence that lutein/zeaxanthin supplementation increases MPOD is well established. A systematic review and meta-analysis of 46 studies in 3,189 healthy adults (PMID 34157098) and a meta-analysis of 20 RCTs in 938 AMD patients and 826 healthy participants (PMID 27420092) both found that supplementation significantly increased MPOD across populations.

Visual Function

A randomized, double-blind, placebo-controlled trial of 115 healthy young adults taking lutein 10 mg + zeaxanthin 2 mg for 1 year (PMID 25468896) found improvements in MPOD, photostress recovery time, and chromatic contrast; glare disability correlated with MPOD but did not significantly improve versus placebo. Additional RCTs in early AMD (PMID 22858124; PMID 25228440) support improvements in macular pigment and selected retinal function outcomes.

Heavy Screen Users — 2025 RCT

A 2025 randomized double-blind placebo-controlled trial of 70 adults with ≥6 hours/day electronic screen use (PMID 39963662) found that lutein 10 mg + zeaxanthin 2 mg for 6 months improved Schirmer tear test scores, photostress recovery, and tear-film break-up time. No significant between-group difference was seen in self-reported visual fatigue or contrast sensitivity. This supports a role for lutein/zeaxanthin in selected objective ocular measures in screen users, while subjective eye-strain benefit was not consistently demonstrated.

Evidence summary for lutein/zeaxanthin:

• AREDS2-type supplementation in intermediate/high-risk AMD — STRONG / ESTABLISHED
• Lutein/zeaxanthin as replacement for beta-carotene — STRONG / SUPPORTED
• Lutein/zeaxanthin → MPOD — MODERATE-TO-STRONG / SUPPORTIVE
• Lutein/zeaxanthin → selected visual-function outcomes — MODERATE / SUPPORTIVE
• Lutein/zeaxanthin in heavy screen users (selected objective measures) — LIMITED / SUPPORTIVE
• Lutein/zeaxanthin for primary AMD prevention in healthy adults — NOT ESTABLISHED

Recommended dose: 10–20 mg/day lutein; 2–4 mg/day zeaxanthin. The AREDS2 trial used 10 mg lutein + 2 mg zeaxanthin.

Astaxanthin

Astaxanthin is a carotenoid produced by microalgae and found in salmon, shrimp, and krill. Based on animal and in vitro data, it is believed to cross the blood-retinal barrier — a property that would allow direct access to retinal tissue — though this has not been directly confirmed in peer-reviewed human pharmacokinetic studies at time of this review. [PRECLINICAL / MECHANISTIC]

Human RCT evidence includes:

• Randomized placebo-controlled trial in 60 healthy adults using astaxanthin 9 mg/day for 6 weeks (PMID 36777084). A significant post-VDT corrected-visual-acuity finding was observed in participants ≥40 years, while several other visual-function outcomes — including functional visual acuity and pupil constriction — did not significantly differ between groups. The age-stratified finding should not be generalized as a broad visual-function benefit across all adults.
• A 2025 RCT in 64 children aged 10–14 with ≥4 hours/day screen use showed improved digital eye strain outcomes with astaxanthin 4 mg/day for 84 days (PMID 40014233) — note this is a pediatric population and results should not be generalized directly to adults. Industry context: Several study authors were employees of AstaReal/Fuji Chemical companies, the astaxanthin manufacturer/supplier ecosystem. This does not invalidate the RCT but is relevant to evidence appraisal.
• A combination trial of anthocyanin, astaxanthin, and lutein in adults with VDT-related eye fatigue supported improvements in accommodation outcomes (PMID 34376917).

A 2012 6 mg/day astaxanthin RCT has been referenced in prior versions of this article; that specific study was not confirmed in PubMed at time of this review and has been removed pending verification.

Evidence summary for astaxanthin:

• Astaxanthin / digital eye strain — LIMITED / SUPPORTIVE
• Astaxanthin / dry eye — LIMITED / INSUFFICIENT
• Astaxanthin / diabetic retinopathy or glaucoma — NOT ESTABLISHED in humans

Human-study doses: Doses vary by formulation and indication; examples include 4 mg/day in the 2025 pediatric digital-eye-strain RCT and 9 mg/day in a 6-week adult visual-function RCT. An optimal clinical dose has not been established.

Omega-7 (Sea Buckthorn Oil / Palmitoleic Acid)

Omega-7 refers to palmitoleic acid, a monounsaturated fatty acid found in sea buckthorn oil and Wild Alaska Pollock oil, with proposed benefits for mucosal tissues including the ocular surface.

The most relevant human trial is a randomized double-blind parallel trial of 100 adults with dry-eye symptoms taking 2 g/day sea buckthorn oil for 3 months (PMID 20554904), which found attenuation of tear-film osmolarity increases and some symptom improvements. A second publication from the same program (PMID 21832964) found no significant group differences in tear-film fatty-acid composition and suggested that benefits may involve carotenoids, tocopherols, or downstream lipid mediators present in sea buckthorn oil — not necessarily direct palmitoleic acid incorporation.

Mechanistic data for palmitoleic acid in a mouse dry-eye model exists (PMID 28379171) but does not constitute human clinical evidence.

Important evidence firewall: Sea buckthorn oil contains multiple fatty acids and antioxidants; it is not equivalent to isolated Omega-7/palmitoleic acid. Bold Vision contains 500 mg Omega-7 from Wild Alaska Pollock — this is not the same preparation as the 2 g/day sea buckthorn oil trial, and the two should not be treated as interchangeable evidence.

Evidence summary for Omega-7:

• Oral sea buckthorn oil / dry eye symptoms — LIMITED / SUPPORTIVE
• Isolated Omega-7 / palmitoleic acid for dry eye — NOT DIRECTLY ESTABLISHED in humans

Recommended dose studied: 2 g/day sea buckthorn oil (not directly comparable to 500 mg isolated Omega-7).

Bilberry Extract

Bilberry (Vaccinium myrtillus) is rich in anthocyanins — flavonoid antioxidants with proposed benefits for retinal blood flow and photoreceptor function.

For VDT-associated eye fatigue, a randomized double-blind placebo-controlled trial in VDT workers using bilberry extract 480 mg/day for 8 weeks (PMID 25923485) found improvements in eye fatigue outcomes. This is the primary evidence supporting bilberry for this indication.

For night vision, a systematic review (PMID 14711439) evaluated the four most methodologically rigorous RCTs and concluded that bilberry anthocyanosides improving normal night vision was not supported by rigorous clinical evidence. Claims that bilberry improves low-light visual acuity in healthy adults are not established.

Dose note: Bold Vision contains 57 mg bilberry extract (20 mg anthocyanins). The VDT eye fatigue trial used 480 mg/day — a substantially higher dose. Results from that trial should not be assumed to apply to the lower dose in this product.

Evidence summary for bilberry:

• Bilberry / VDT-associated eye fatigue — LIMITED / SUPPORTIVE (at 480 mg/day)
• Bilberry / normal night vision — NOT ESTABLISHED

Featured Product: Wiley's Finest® Bold Vision

Wiley's Finest® Bold Vision (60 Softgels — 30 Servings)

Per 2-softgel serving: Lutein 20 mg • Zeaxanthin 4 mg • Omega-7 500 mg • Astaxanthin 2 mg • Bilberry Extract 57 mg (20 mg anthocyanins) • Zinc 11 mg (100% DV) • Vitamin E 20 mg. From Wild Alaska Pollock (MSC-certified). Made in USA. Free from 13 common allergens.

PharmD note: Bold Vision combines ingredients studied across macular pigment, visual-function, and ocular-surface research in a convenient 2-softgel daily serving. It delivers lutein/zeaxanthin in the same 5:1 ratio used in AREDS2 (20 mg:4 mg in Bold Vision vs 10 mg:2 mg in AREDS2), Omega-7 from a sustainable pollock source, astaxanthin, and bilberry anthocyanins. Note that the finished combination has not itself been evaluated in clinical trials; ingredient-level evidence does not constitute direct proof of finished-product efficacy.

Who Benefits Most from Eye Health Supplementation

• 🟢 Patients with intermediate AMD or advanced AMD in one eye — AREDS2-type supplementation with lutein/zeaxanthin has the strongest evidence base for this group specifically
• 🟢 Former smokers on AREDS-type supplements — lutein/zeaxanthin is the safer beta-carotene replacement; avoid high-dose beta-carotene
• 🟢 Adults with dry eye symptoms — oral sea-buckthorn oil has limited supportive human evidence; evidence for isolated Omega-7 and astaxanthin as dry-eye treatments is not established. Discuss persistent symptoms with an eye-care professional.
• 🟢 Heavy screen users (≥6 h/day) — lutein/zeaxanthin shows benefit for selected objective ocular measures; subjective eye strain results are mixed
• 🟡 Adults 40+ with family history of AMD — supplementation may be considered; discuss with your eye care provider as primary prevention evidence in healthy adults is not established
• 🟡 Diabetic patients — antioxidant support is commonly discussed; however, supplementation has not been established to prevent diabetic retinopathy
• 🔴 Fish allergy — Bold Vision contains Alaska Pollock; contraindicated

Drug Interactions — What Pharmacists Need You to Know

• Anticoagulants/antiplatelets: No well-established clinically significant interaction with the Omega-7 dose in this product has been demonstrated in humans. Patients taking warfarin, apixaban, or multiple antiplatelet agents should nevertheless review all supplements with their pharmacist before starting.
• Beta-carotene supplements: High-dose beta-carotene nearly doubled lung cancer risk in former smokers in the 10-year AREDS2 follow-up. Avoid combining high-dose beta-carotene with lutein/zeaxanthin supplements; the AREDS2 reformulation specifically replaced beta-carotene with lutein/zeaxanthin for this reason.
• Zinc: High-dose zinc (80 mg/day as in original AREDS) can interfere with copper absorption. Bold Vision contains 11 mg zinc — a moderate dose that does not require copper supplementation at this level.
• Fish allergy: Bold Vision is derived from Wild Alaska Pollock and is contraindicated in fish allergy.

Evidence Summary

Pharmacist's Bottom Line

Eye health supplementation has a meaningful and well-characterized evidence base for specific populations — particularly patients with intermediate or high-risk AMD. AREDS2 and its long-term follow-up support lutein and zeaxanthin as the preferred replacement for beta-carotene in AREDS-type supplementation, particularly given the beta-carotene lung-cancer signal and supportive secondary analyses of AMD progression. Evidence for MPOD increase and selected visual-function improvements is consistent. Astaxanthin and sea buckthorn oil provide additional supportive evidence for digital eye strain and dry eye symptoms, respectively, though the evidence base for each is more limited and does not extend to AMD prevention or treatment of established eye disease.

As a pharmacist, I discuss Wiley's Finest Bold Vision as a convenient combination product for patients who are already candidates for AREDS-aligned supplementation or who have evidence-based risk factors. I do not present it as a prevention tool for healthy adults without risk factors, nor as a treatment for established eye disease. Individual suitability depends on your full health history and medication list.

Our PharmD team is available for free consultations — call (408) 622-8068 or visit us in-store in San Jose.

Key References

• RCTAREDS2 Research Group. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The AREDS2 RCT. JAMA. 2013. PMID: 23644932
• SECONDARY ANALYSISChew EY, et al. Secondary Analyses of AREDS2: Beta-Carotene Substitution for Lutein/Zeaxanthin. JAMA Ophthalmol. 2014. PMID: 24310343
• 10-YEAR FOLLOW-UPChew EY, et al. Long-Term Outcomes of Adding Lutein/Zeaxanthin and Omega-3 Fatty Acids to the AREDS Supplements. JAMA Ophthalmol. 2022. PMID: 35653117
• SYSTEMATIC REVIEW / META-ANALYSISWilson LM, et al. The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis. Advances in Nutrition. 2021. PMID: 34157098
• META-ANALYSISMa L, et al. Lutein and Zeaxanthin Supplementation and MPOD: A Systematic Review and Meta-Analysis. PMID: 27420092
• HUMAN RCTNolan JM, et al. Macular Pigment, Visual Performance and Learning. PMID: 25468896
• 2025 RCTPMID 39963662 — Lutein/zeaxanthin in heavy screen users; tear film and photostress outcomes.
• 2025 RCTPMID 40014233 — Astaxanthin 4 mg/day in children with digital eye strain (pediatric population; industry author involvement: AstaReal/Fuji Chemical).
• HUMAN RCTPMID 36777084 — Astaxanthin 9 mg/day in 60 healthy adults for 6 weeks; significant post-VDT corrected-visual-acuity finding in ≥40 subgroup only; functional visual acuity and pupil constriction did not significantly differ between groups.
• HUMAN RCTLarmo PS, et al. Oral Sea Buckthorn Oil Attenuates Tear Film Osmolarity and Symptoms in Individuals with Dry Eye. PMID: 20554904
• HUMAN RCTPMID 21832964 — Sea buckthorn oil; tear-film fatty acids and mechanisms.
• HUMAN RCTPMID 25923485 — Bilberry extract 480 mg/day in VDT workers; eye fatigue outcomes.
• SYSTEMATIC REVIEWCanter PH, Ernst E. Anthocyanosides of Vaccinium myrtillus for Night Vision — A Systematic Review of Placebo-Controlled Trials. PMID: 14711439

Frequently Asked Questions

Q: At what age should I start taking eye health supplements?
A: The strongest evidence for supplementation is in patients with intermediate AMD or advanced AMD in one eye. For healthy adults with family history or significant risk factors, supplementation may be considered — discuss with your eye care provider. There is no established evidence base for universal supplementation starting at age 40 in healthy adults without risk factors.

Q: Can eye supplements reverse AMD?
A: No. AREDS2-type supplementation does not reverse AMD. In appropriate patients, it is used to reduce the risk of progression to late/advanced AMD.

Q: Do blue light glasses replace the need for lutein supplements?
A: These address different pathways. Blue light glasses filter external light at the lens surface; lutein and zeaxanthin are deposited in the macula itself. They are complementary, not interchangeable. Note that screen use is primarily associated with eye strain and dry eye — the link between everyday screen blue light and retinal degeneration is not established.

Q: How long before I notice results?
A: Macular pigment density increases measurably within 3–6 months of consistent lutein/zeaxanthin supplementation in clinical studies. Omega-7 / dry eye improvements were noted over a 3-month trial period in the sea buckthorn oil RCT.

Related Clinical Insights Articles

• Vitamin D3 + K2: Why You Need Both →
• Magnesium: The Most Underrated Mineral →
• Resveratrol and Longevity: A Pharmacist's Evidence Review →

Reviewed by

Dai Tran, PharmD, MBA, B.S. • View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is written for educational purposes by the Khang Pharmacy PharmD team and does not replace consultation with your healthcare provider or eye care specialist.